Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.38 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.38 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.38 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.38 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.38 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.38 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.38 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.38 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | THPO | P40225 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL30255056 | 0.98 | PNMT (0.53) | PNMTADRA2AADRA2BADRA2CADCY6 | |
| SCHEMBL23683887 | 0.85 | PNMT (0.52) | PNMTADRA2AADRA2BADRA2CDRD1 | |
| SCHEMBL23684460 | 0.84 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CDRD1 | |
| SCHEMBL3095722 | 0.75 | PNMT (0.71) | PNMTADRA2AADRA2BADRA2CDRD1 | |
| Bromide SCHEMBL3091461 | 0.74 | PNMT (0.68) | PNMTADRA2AADRA2BADRA2CDRD1 | |
| Bromide SCHEMBL31018188 | 0.74 | PNMT (0.68) | PNMTADRA2AADRA2BADRA2CDRD1 | |
| SCHEMBL16518065 | 0.73 | PNMT (0.53) | PNMTADRA2AADRA2BADRA2CHTR2B | |
| SCHEMBL22993478 | 0.72 | HTR2A (0.50) | PNMTADRA2AADRA2BADRA2CDRD1 | |
| SCHEMBL11725343 | 0.71 | ADCY6 (0.43) | PNMTADRA2AADRA2BADRA2CADCY6 | |
| SCHEMBL20522616 | 0.71 | PNMT (0.52) | PNMTADRA2AADRA2BADRA2CADCY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601258-B1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3601258-B1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-110461829-B | Substituted isoquinoline derivatives as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200181125-A1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181125-A1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3601258-A1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | Bristol-Myers Squibb Company (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183171-A1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181125-A1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | CD74, HLA-DRB1, ICOS | PNMT 118/4885ADRA2A 2606/4885ADRA2B 2695/4885 |
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | CD74, HLA-DRB1, ICOS | PNMT 118/4885ADRA2A 2606/4885ADRA2B 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.